Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Lidak Pharm. [LDAKA] -- Ignore unavailable to you. Want to Upgrade?

To: John Zwiener who wrote (830)	1/13/1998 4:51:00 PM
From: Red Dragon	Read Replies (1) \| Respond to of 1115

Lidak gets some good press. This is probably the reason for Lidak's recent spurt. Again, my hunch is that Lidakol is not as big a blockbuster as some statements portray it to be. However, it is so harmless that even marginal efficacy might convince the FDA to approve it. Still have to wonder about the Bristol Myers decision... John. Thanks for pointing out the Yahoo message board. Can you post or link significant messages from there on to SI from time to time? This excerpt was taken from there: This is the meaningful portion of the LA Times article mentioned in 233. Progress on Oral Herpes - People with recurrent oral herpes simplex virus, known as the fever blister or cold sore, may soon have another option for treatment. Lidak, a biotech company in La Jolla, has requested clearance to market Lidakol. Lidakol is a topical cream that would be the first treatment for herpes outbreaks that, when used early enough, can abort further development of a recurrent herpes episode before it reaches the blister stage. The drug would be available by prescription only, although company officials say they hope to move the product to over-the-counter status as soon as the FDA permits. As any herpes sufferer knows, anything to reduce the pain, itching, tingling and burning is a welcome relief. About 80% of adults are infected with herpes and about one-third of those who are infected have recurrent outbreaks. There is no cure for herpes. Over-the-counter products to relieve symptoms have traditionally been disappointing. The approval of Lidakol would be good news indeed.

To: John Zwiener who wrote (830)	1/13/1998 6:51:00 PM
From: luis a. garcia	Respond to of 1115

I thought Hniman was a bit too negative about the stock... just didn't know why....till now...what a rascal... luis